98 related articles for article (PubMed ID: 28263209)
1. The Wandering Mesenteric Lymph Node: Delayed 68Ga-DOTANOC PET/CT Imaging to Overcome a Potential Pitfall.
Zanoni L; Zompatori M; Scalorbi F; Fanti S; Ambrosini V
Clin Nucl Med; 2017 May; 42(5):e253-e254. PubMed ID: 28263209
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
4. 3P's of Wermer/MEN1 Syndrome on 68Ga-DOTANOC PET/CT Scan.
Tripathy S; Prakash S; Arun Raj ST; Kumar A; Shamim SA
Clin Nucl Med; 2020 Dec; 45(12):e516-e517. PubMed ID: 32796241
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma.
Sharma P; Arora S; Karunanithi S; Khadgawat R; Durgapal P; Sharma R; Kandasamy D; Bal C; Kumar R
Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):69-76. PubMed ID: 24740163
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes.
Sharma P; Mukherjee A; Karunanithi S; Naswa N; Kumar R; Ammini AC; Bal C
Clin Nucl Med; 2015 Jul; 40(7):e351-6. PubMed ID: 25783509
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors.
Ambrosini V; Campana D; Bodei L; Nanni C; Castellucci P; Allegri V; Montini GC; Tomassetti P; Paganelli G; Fanti S
J Nucl Med; 2010 May; 51(5):669-73. PubMed ID: 20395323
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-DOTANOC PET/CT in Multiple Endocrine Neoplasia 1 With Associated Adrenocortical Carcinoma.
Basheer S; Ratheesan R; Sarma M; Palaniswamy SS; Mathews A
Clin Nucl Med; 2022 May; 47(5):e389-e392. PubMed ID: 35195585
[TBL] [Abstract][Full Text] [Related]
10. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK
World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
[TBL] [Abstract][Full Text] [Related]
11. Gastric Mucosal Hypertrophy Masquerading as Metastasis From Neuroendocrine Tumor of the Pancreas Detected on 68Ga-DOTANOC PET/CT.
Malik D; Elumalai R; Verma R; Belho ES; Seniaray N; Mahajan H
Clin Nucl Med; 2020 Jan; 45(1):74-75. PubMed ID: 31693612
[TBL] [Abstract][Full Text] [Related]
12. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma.
Tabacchi E; Campana D; Brighi N; Fanti S; Ambrosini V
Clin Nucl Med; 2019 Mar; 44(3):238-239. PubMed ID: 30672751
[TBL] [Abstract][Full Text] [Related]
14. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.
Berzaczy D; Giraudo C; Haug AR; Raderer M; Senn D; Karanikas G; Weber M; Mayerhoefer ME
Clin Nucl Med; 2017 Sep; 42(9):669-674. PubMed ID: 28682844
[TBL] [Abstract][Full Text] [Related]
15. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation.
Christiansen CD; Petersen H; Nielsen AL; Detlefsen S; Brusgaard K; Rasmussen L; Melikyan M; Ekström K; Globa E; Rasmussen AH; Hovendal C; Christesen HT
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):250-261. PubMed ID: 29116340
[TBL] [Abstract][Full Text] [Related]
16. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
[TBL] [Abstract][Full Text] [Related]
17. The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm.
Rufini V; Inzani F; Stefanelli A; Castaldi P; Perotti G; Cinquino A; Indovina L; Rindi G
Pancreas; 2017 Feb; 46(2):157-163. PubMed ID: 27846139
[TBL] [Abstract][Full Text] [Related]
18. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
19. Metastatic neuroendocrine carcinoma presenting as a "Superscan" on 68Ga-DOTANOC somatostatin receptor PET/CT.
Naswa N; Karunanithi S; Soundararajan R; Das KJ; Agarwal KK; Malhotra A; Bal C; Kumar R
Clin Nucl Med; 2012 Sep; 37(9):892-4. PubMed ID: 22889781
[TBL] [Abstract][Full Text] [Related]
20. ⁶⁸Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin.
Naswa N; Sharma P; Kumar A; Soundararajan R; Kumar R; Malhotra A; Ammini AC; Bal C
Clin Nucl Med; 2012 Mar; 37(3):245-51. PubMed ID: 22310250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
